What is a stock summary page? Click here for an overview.
Business Description
Intensity Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US45828J1034
Description
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 18.77 | |||||
| Equity-to-Asset | 0.61 | |||||
| Debt-to-Equity | 0.05 | |||||
| Debt-to-EBITDA | -0.01 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -24.9 | |||||
| 3-Year EPS without NRI Growth Rate | -24.7 | |||||
| 3-Year FCF Growth Rate | -28.1 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 21.07 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 41.48 | |||||
| 9-Day RSI | 41.24 | |||||
| 14-Day RSI | 42.92 | |||||
| 3-1 Month Momentum % | 13.7 | |||||
| 6-1 Month Momentum % | -43.85 | |||||
| 12-1 Month Momentum % | -59.37 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.92 | |||||
| Quick Ratio | 1.92 | |||||
| Cash Ratio | 1.48 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -4.9 | |||||
| Shareholder Yield % | -5.55 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -239.76 | |||||
| ROA % | -168.16 | |||||
| ROIC % | -946.52 | |||||
| 3-Year ROIIC % | 727.27 | |||||
| ROC (Joel Greenblatt) % | -12086.18 | |||||
| ROCE % | -234.96 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 10.68 | |||||
| Price-to-Tangible-Book | 10.68 | |||||
| EV-to-EBIT | -1.76 | |||||
| EV-to-EBITDA | -1.76 | |||||
| EV-to-FCF | -1.88 | |||||
| Price-to-Net-Current-Asset-Value | 20.3 | |||||
| Price-to-Net-Cash | 40.6 | |||||
| Earnings Yield (Greenblatt) % | -56.82 | |||||
| FCF Yield % | -49.38 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:INTS
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Intensity Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -1.17 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 79.92 | ||
| 14-Day RSI | 42.92 | ||
| 14-Day ATR ($) | 0.243527 | ||
| 20-Day SMA ($) | 2.214245 | ||
| 12-1 Month Momentum % | -59.37 | ||
| 52-Week Range ($) | 1.5 - 5.48 | ||
| Shares Outstanding (Mil) | 15.18 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Intensity Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Intensity Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Intensity Therapeutics Inc Frequently Asked Questions
What is Intensity Therapeutics Inc(INTS)'s stock price today?
The current price of INTS is $2.03. The 52 week high of INTS is $5.48 and 52 week low is $1.50.
When is next earnings date of Intensity Therapeutics Inc(INTS)?
The next earnings date of Intensity Therapeutics Inc(INTS) is 2025-05-09 Est..
Does Intensity Therapeutics Inc(INTS) pay dividends? If so, how much?
Intensity Therapeutics Inc(INTS) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers